Tehniat Faraz Ahmed

Tehniat Faraz Ahmed

Auto-generated profile, based on publicly available information

Tehniat Faraz Ahmed

Department of Biochemistry, Dow International Dental College, Dow University of Health Sciences, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Expert Review of Vaccines
Verified
Journal Article
Closed access
TATehniat F Ahmed
Tehniat F Ahmed
AAAffan Ahmed
Affan Ahmed
SASheharyar Ahmed
Sheharyar Ahmed
HAHaadi U Ahmed
Haadi U Ahmed
As countries ramp up their COVID-19 vaccination programs, attitudes of the population remain a determining player in the success of these plans. This study analyses the factors associated with inte...

1 May 2021 in Brain Research
Verified
Journal Article
Closed access
TATehniat F. Ahmed
Tehniat F. Ahmed
AAAffan Ahmed
Affan Ahmed
FIFauzia Imtiaz
Fauzia Imtiaz

1 July 2021 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
KNKarun Neupane
Karun Neupane
AWAhsan Wahab
Ahsan Wahab
AMAdeel Masood
Adeel Masood
TFTehniat Faraz
Tehniat Faraz
SBSaman Bahram
Saman Bahram
FAFaiz Anwer
Faiz Anwer
Treatment options are limited for multiple myeloma patients who have developed four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs is a concern since these agents are used in patients who have already undergone multiple lines of treatment. In this review, we discuss the toxicity profile and strategies for the management of toxicities of Sel and belamaf for the treatment of RRMM. We conducted a comprehensive literature search on PubMed, Embase, Cochrane, and Clinicaltrials.gov using the terms “selinexor”, “belantamab”, “belamaf”, and “multiple myeloma” without applying any limitations based on the date of the study, language, or country of origin. The most common hematological toxicity associated with these two drugs is thrombocytopenia. Cytopenias, constitutional symptoms, gastrointestinal effects, and hyponatremia are the major toxicities of Sel. Keratopathy and anemia are the major toxicities of belamaf. Treatment modifications and dose interruption are usually needed when side effects are more than grade II. As these are newer drugs with limited data, continuous surveillance and monitoring are warranted during the treatment course with early mitigation strategies.

15 September 2021 in Expert Review of Hematology
Verified
Journal Article
Closed access
ASAyesha Sarwar
Ayesha Sarwar
LHLaila Hashim
Laila Hashim
MFMuhammad Salman Faisal
Muhammad Salman Faisal
MHMobeen Zaka Haider
Mobeen Zaka Haider
ZAZahoor Ahmed
Zahoor Ahmed
FAFaiz Anwwer
Faiz Anwwer
Introduction: Oncolytic viruses are genetically engineered viruses that target myeloma-affected cells by detecting specific cell surface receptors (CD46, CD138), causing cell death by activating the signaling pathway to induce apoptosis or by immune-mediated cellular destruction. Although MM is a highly treatable but incurable disease, therapeutic advances with oncolytic viruses are an innovative treatment approach. Areas covered: This article summarizes oncolytic virotherapy advancements such as the therapeutic use of viruses by targeting cell surface proteins of myeloma cells as well as the carriers to deliver viruses to the target tissues safely. The major classes of viruses that have been studied for this include measles, myxoma, adenovirus, reovirus, vaccinia, vesicular-stomatitis virus, coxsackie, and others. The measles virus acts as oncolytic viral therapy by binding to the CD46 receptors on the myeloma cells to utilize its surface H protein. These H-protein and CD46 interactions lead to cellular syncytia formation resulting in cellular apoptosis. Vesicular-stomatitis virus acts by downregulation of anti-apoptotic factors (Mcl-2, BCL-2). Based upon the published literature searches till December 2020, we have summarized the data supporting the advances in viral oncolytic for the treatment of MM. Expert opinion: Oncolytic virotherapy is an experimental approach in multiple myeloma (MM); many issues need to be addressed for safe viral delivery to the target tissue.

1 July 2023 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
TATehniat Faraz Ahmed
Tehniat Faraz Ahmed
MAMuhammad Bilal Azmi
Muhammad Bilal Azmi
FIFauzia Imtiaz
Fauzia Imtiaz
UZUzma Zaman
Uzma Zaman
AAAffan Ahmed
Affan Ahmed
NSNaila Shahbaz
Naila Shahbaz
The National Institute on Aging-Alzheimer's Association's research framework in 2018 proposed a molecular construct for the diagnosis of Alzheimer’s disease (AD). Nonetheless, the clinical exclusionary strategy is still the mainstay of AD diagnosis in Pakistan. We looked at the plasma levels of amyloid beta-42 (Aβ-42), phosphorylated tau (P-tau), and neurofilament light (NFL) in patients with Alzheimer's clinical syndrome (ACS) and healthy controls (HC) from the Pakistani population to keep pace with the global efforts towards establishing accessible and affordable biochemical diagnostic markers for AD in Pakistan.

15 July 2023 in Journal of the Pakistan Medical Association
Verified
Journal Article
Open access
PDF file
TATehniat Faraz Ahmed
Tehniat Faraz Ahmed
AAAffan Ahmed
Affan Ahmed
QHQuratulain Humayun
Quratulain Humayun
SSSyed Hamza Sohail
Syed Hamza Sohail
FIFauzia Imtiaz
Fauzia Imtiaz
Objectives: To qualitatively analyse the barriers in pursuing undergraduate research, and to propose solutions for the problems identified. Method: The qualitative study was conducted from May to October 2021 after approval from the institutional ethics review board of the Dow University of Health Sciences, Karachi, and comprised undergraduate students of either gender at various public and private medical universities across Pakistan having some level of research experience and good communication skills. Data triangulation was employed to collect qualitative data through open-ended survey, face-to-face interviews and focus group discussions. Using the information of one method to inform the rest, linked trajectories were established that allowed validation of information at each level. Data was coded manually by two researchers independently. Data was subjected to inductive thematic analysis. Results: Of the 33 subjects, 17(51.5%) were males, 17(51.5%) were from private medical colleges, 18(54.5%) were from Karachi, and 11(33.3%) were in the final year of medical school. Overall, 13(39.4%) students completed the open-ended survey, 6(18.2%) completed face-to-face interviews, and 14(42.4%) participated in focus group discussions. Thematic anlsysis showed that students were interested in research to improve their career prospects, but not all were passionate about it. Students were not satisfied with the quality of research being conducted Pakistan in the country. Dearth of motivated faculty, unavailability of well-maintained and digitalised data registries, ineffective research methodology teaching and lack of access to medical journals and research software were the major barriers in undergraduate research. Time constraint was a projecting problem which challenged the students. Frequent research workshops and conferences, strong networking, reorienting curriculum to provide early exposure to research and student-led initiatives were suggested to improve undergraduate research in Pakistan. Conclusion: Students’ lack of initiative coupled with administrative and faculty-related issues pose a serious threat to the future of evidence-based medicine. Proposed solutions offer a ray of hope to the future of undergraduate research in Pakistan. Key Words: Undergraduate medical education, Qualitative research, Focus groups, Interview, Pakistan.